| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Revenue | 2,941 | 2,681 |
| Pretax Income | 597.00 | 218.00 |
| Net Income | 436.00 | 179.00 |
| Diluted EPS | 1.15 | 0.48 |
- Net Income YoY
- +143.6%
Key highlights
- Consolidated revenue grew to $2,941 million, up from $2,681 million in the prior-year period
- Net income surged 143.6% year-over-year to $436 million, or $1.15 per diluted share
- Pretax income improved to $597 million compared to $218 million in Q3 2025
- Full-year 2026 consolidated revenue guidance raised to a range of $10,975–$11,175 million
- Cash and cash equivalents increased to $2.49 billion as of September 30, 2026
How the Period Went
Bausch Health achieved revenue of $2,941 million in the third quarter of 2026, marking a 9.7% increase over the $2,681 million reported in the same period last year. This top-line expansion was accompanied by a significant 143.6% surge in net income, which rose to $436 million from $179 million in Q3-25. Consequently, diluted earnings per share reached $1.15, up from $0.48. These results reflect consistent operational momentum across the company's core segments, particularly within the Salix and Solta Medical units, which benefited from robust demand for gastroenterology and aesthetic treatments respectively.
Margins and Profitability
Pretax income for the quarter reached $597 million, a substantial improvement from the $218 million recorded in the prior-year period. This profitability growth was supported by a 230 basis point expansion in adjusted gross margins to 75%, driven by favorable product mix and improved realized pricing in the Salix segment. While the company saw a decrease in total assets to $25.48 billion—primarily due to the reduction of goodwill and intangible assets—it significantly bolstered its liquidity position. Cash and cash equivalents reached $2.49 billion by the end of September 2026, facilitating a net debt reduction of $521 million during the quarter.
Business Overview
- Salix Pharmaceuticals: Focused on gastroenterology and hepatology treatments, anchored by the Xifaxan franchise
- Solta Medical: Global aesthetics segment providing skin-tightening and resurfacing technologies
- Bausch + Lomb: Controlling interest in the publicly traded eye health leader covering vision care and surgical products
- International & Diversified: Managing a portfolio of established brands across dermatology, neurology, and dentistry
- Pipeline Development: Recent initiation of Phase 3 registrational programs for Larsucosterol in alcohol-associated hepatitis
Financial Context
The third quarter performance represents the fourteenth consecutive quarter of year-over-year revenue growth for Bausch Health, excluding its interest in Bausch + Lomb. Following quarterly revenues of $2.52 billion in Q1 and $2.85 billion in Q2, the $2,941 million reported in Q3 led management to raise its full-year 2026 consolidated revenue guidance to a range of $10,975 million to $11,175 million. The company is also actively managing its balance sheet, with a scheduled redemption of approximately $643 million in senior notes due in 2027, highlighting a strategic shift toward deleveraging and financial stabilization.
Industry Landscape
The pharmaceutical industry in 2026 is navigating a landscape of steady demand for specialty medicines and medical devices, balanced against pricing pressures in competitive markets. In the gastroenterology space, Bausch Health’s Xifaxan continues to maintain a leading position, though the sector anticipates headwinds from new Medicare pricing adjustments scheduled for 2027. Peer companies such as Teva and Viatris have similarly prioritized portfolio optimization and debt reduction to address legacy obligations. Meanwhile, the medical aesthetics market remains a high-growth area, with Bausch’s Solta Medical segment benefiting from international distribution expansion despite broader macroeconomic softening in specific regions.
| Date | Announcement | Amount |
|---|---|---|
| 28 Oct 2026 | Q3 2026 consolidated revenues and raised FY 2026 guidanceSource: fool.com | $2.94 Billion |
| 29 Jul 2026 | Q2 2026 consolidated revenues and raised FY 2026 guidanceSource: ir.bauschhealth.com | $2.85 Billion |
| 29 Apr 2026 | Q1 2026 consolidated revenues and reaffirmed FY 2026 guidanceSource: ir.bauschhealth.com | $2.52 Billion |
| 18 Feb 2026 | Q4 2025 consolidated revenues and FY 2026 guidance initiationSource: ir.bauschhealth.com | $2.80 Billion |
| 29 Oct 2025 | Q3 2025 consolidated revenues and raised FY 2025 guidanceSource: ir.bauschhealth.com | $2.68 Billion |
| 30 Jul 2025 | Q2 2025 consolidated revenues and reaffirmed FY 2025 guidanceSource: ir.bauschhealth.com | $2.53 Billion |
SEC filing by Bausch Health Companies Inc. announcing third quarter 2026 financial results.
Track Bausch Health Companies Inc. live
Get the next Bausch Health Companies Inc. SEC filing seconds after it lands.



